Abbreviations: LOS ϭ length of stay; MOSF ϭ multiple-organ system failure; MRSA ϭ methicillin-resistant Staphylococcus aureus; PSB ϭ protected specimen brush; URI ϭ upper respiratory tract illness
I
nfluenza A virus accounts for significant morbidity and mortality despite major efforts in prevention and treatment. 1 Thousands of deaths occur and billions of dollars are spent each year for influenzarelated illnesses. [1] [2] [3] Morbidity and mortality have largely been attributed to the development of respiratory complications, and management has mainly consisted of supportive care and treatment of superimposed bacterial infections. [1] [2] [3] The difficulty in confirming the diagnosis of influenza A infection in patients with community-acquired pneumonia has
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limited the use of antiviral agents in these patients. Recently, rapid diagnostic tests have become available for the diagnosis of influenza, and a new class of therapeutic agents (neuraminidase inhibitors) has been approved for use in patients with influenza. The impact of these advances on the recognition and treatment of influenza pneumonia is unclear. We therefore reviewed all cases of patients with influ-enza admitted to a large metropolitan referral hospital in Washington, DC from December 1999 to February 2000. Clinical course, treatment, and associated morbidity and mortality are described in detail on cases complicated by pneumonia. The results are compared to previous studies.
Materials and Methods

Subjects
One hundred thirty-nine patients between the ages of 25 years and 92 years admitted to Washington Hospital Center, Washington, DC from December 1999 to February 2000 with upper or lower respiratory tract symptoms were tested for influenza A. The hospital charts of the patients with positive findings for influenza A were reviewed. Influenza pneumonia was defined by a new pulmonary infiltrate on the chest radiograph. Influenza upper respiratory tract illness (URI) was defined by fever, chills, nasal discharge, and cough with or without sputum, but with a clear chest radiograph. In addition, the hospital records of all medical admissions from December to February for the last 5 years were reviewed to identify patients with diagnosed influenza. The number of cases of influenza patients admitted to the hospital during each influenza "season" was recorded.
Microbiological Methods
Either a direct enzyme immunoassay (Directigen; BD Diagnostic Systems; Sparks, MD) or an endogenous viral-encoded enzyme assay (ZstatFlu; ZymeTx; Oklahoma City, OK) was used to test for influenza A. The sensitivities and specificities for these tests have been reported to range from 65 to 96% and 90 to 99%, respectively. 4 -8 Samples from suspected patients were obtained by a nasopharyngeal wash as recommended by the test manufacturer. Bronchial washings were also tested in selected cases. The first five tests performed had culture confirmation by centrifugation-enhanced rapid viral culture, 9 which confirmed the test results in all five cases (three positive and two negative results). Tracheal aspirates and blind protected specimen brush (PSB) sampling with quantitative bacterial culture were performed in intubated patients. A quantitative threshold of 500 cfu/mL was used for the PSB. Bronchoscopy with BAL was performed as clinically indicated. A quantitative threshold of 5,000 cfu/mL was used for the BAL specimens. Complicating bacterial pneumonia was diagnosed in patients with quantitative cultures above these predefined thresholds.
Data Collection and Analysis
The patients' demographic and clinical data were recorded in an electronic spreadsheet (Excel 2000; Microsoft; Redmond, WA). At the end of the data collection, summary statistics were compiled to allow a description of the patients with and without pneumonia. Statistical analysis was done using NCSS 2000 (NCSS Statistical Software; Kaysville, UT). 2 analysis with Fisher's Exact Test (when appropriate) was used to compare categorical data. Continuous data were compared using Student's t test. Unless otherwise stated, all data are expressed as mean (with range) or percentages, with statistical significance declared for probability values of Յ 0.05.
Results
During each of the past five influenza seasons, influenza was diagnosed in five to eight patients. Thirty-five of the 139 patients (25%) tested between December 1999 and February 2000 had positive findings for influenza A. Of the 35 patients, 17 patients (48.5%) developed influenza pneumonia and the other 18 patients had influenza URI. Demographics and baseline characteristics of the influenza patients with and without pneumonia are shown in Table 1 . The male/female ratio was 1:1.3 (15 men and 20 women); most patients were black (29 patients; 82.9%). The mean age was 57 years (range, 25 to 94 years). The characteristics of the patients who developed influenza pneumonia were similar to those with URI except they tended to be older (63 Ϯ 13 years vs 51 Ϯ 19 years, respectively; p ϭ 0.04). Serious comorbid illnesses, such as heart disease, diabetes, and renal disease, and organ transplantation were found frequently in both the pneumonia group and the URI group; however, a history of chronic respiratory disease was more common in the pneumonia group (41% vs 6%, respectively; p ϭ 0.02). AIDS, lymphoma, smoking, and alcohol abuse did not appear to be important factors in this study. The mean durations of symptoms prior to hospital admission for the pneumonia group and the URI group were 2 days (range, 1 to 7 days) and 3.3 days (range, 1 to 10 days), respectively (not significant). Although small, this difference suggests that patients with pneumonia were more symptomatic, as seen by their more frequent complaints of shortness of breath (82.3% vs 17%, respectively; p ϭ 0.002), and sought medical attention earlier in the disease course. Other complaints, such as cough (82%), fever or chills (80%), and myalgias (31%), were equally seen in both groups. Fever was the most frequent physical finding (mean hospital admission temperature of 38.3°C). No consistent laboratory abnormalities were noted except for a high serum lactate dehydrogenase level (mean, 304 U/L; range, 130 to 711 U/L). Influenza vaccination data were available in 24 of the 35 patients (68.6%) included in this study, 14 in the URI group and 10 in the pneumonia group. Seven of the 14 patients (50%) in the URI group and 2 of the 10 patients (20%) in the pneumonia group had been vaccinated in the fall of 1999. Vaccination data were available in two of the five patients who died, and both had not been vaccinated. High morbidity was associated with both vaccinated and unvaccinated patients in whom pneumonia developed. No significant difference was observed in length of stay (LOS) between vaccinated and unvaccinated patients (mean, 4.6 days and 4.7 days, respectively); however, only two of the nine vaccinated patients (22.2%) developed pneumonia. The hospital features of the patients with influenza pneumonia are presented in Table 2 . The number of days (mean Ϯ SD) between the onset of symptoms and start of antiviral treatment was similar between the patients who died (4.5 Ϯ 2.5 days) and survived (4.1 Ϯ 3.0 days). Antiviral treatment was administered to 14 of the 17 patients (82%) with pneumonia, and consisted of oseltamivir (35%), rimantadine (6%), or a combination of both (41%). Antiviral medications were well tolerated and administered for a total of 5 days in most patients. Bilateral diffuse interstitial/alveolar infiltrates were seen as the most common radiographic abnormality (nine patients; 52%), followed by right lower lobe consolidation in six patients (35%). Blood cultures were obtained from all 17 patients; 4 of the ICU patients had positive culture findings (Staphylococcus aureus in 3 patients and Streptococcus pneumoniae in 1 patient). Respiratory tract cultures were obtained from all ICU patients (n ϭ 10; Table 2 ). Respiratory tract culture findings were positive in five of these patients, four of whom were also bacteremic. S aureus was isolated in five patients, and S pneumoniae was isolated in one patient. Of the five patients with positive culture findings for S aureus, four patients (80%) had methicillin-resistant strains.
Of the 17 patients with influenza pneumoniae, 10 patients (58.8%) were admitted to the ICU; 5 of these patients died (Table 2) . Overall, there was a 29.4% mortality rate. Patients who died had similar APACHE (acute physiology and chronic health evaluation) II scores as survivors (18.5 Ϯ 8.5 vs 16.5 Ϯ 14.5, respectively). Of the five patients who died, four patients had bilateral infiltrates observed on their chest radiographs. Although most patients who died had serious comorbid illnesses (four patients), of the two patients with no comorbid illness who developed pneumonia, one patient died. Ten patients (58.8%) received mechanical ventilation for a mean of 20.4 days (range, 1 to 42 days), and tracheostomy was performed in four patients (23%) due to failure to wean. The lowest Pao 2 /fraction of inspired oxygen was 230 (90 to 280) in the survivors, compared to 91 (54 to 185) in the nonsurvivors (p ϭ 0.005). The number of ventilator days was 18.4 (range, 10 to 42 days) in the survivors, compared to 22.4 days (range, 1 to 39 days) in the nonsurvivors (not significant). All patients were treated with broad-spectrum antibiotics from day 1. The mean hospital LOS was 19.1 days (range, 2 to 4 days), and death was attributed to respiratory failure and/or multiple-organ system failure (MOSF). No deaths were recorded in the URI group. Levofloxacin, vancomycin, and cephalosporins were the most commonly administered antibiotics. The mean antibiotic days (the number of antibiotic medications times the number of days of treatment) was 17.4 days (range, 0 to 42 days), and levofloxacin was the most commonly administered antibiotic for empiric coverage (14 patients; 82%).
Discussion
In this article, we describe our experience with influenza A virus respiratory complications during the 1999 -2000 influenza season. An important observations in this study was the increased (fourfold to seven fold) recognition of influenza A infection. This is likely due to the availability of the recently marketed influenza antigen tests that allow for the rapid diagnosis of influenza, and the increased public awareness of influenza due to the intense media coverage of this subject. Other findings of this study include the association of influenza pneumonia with serious comorbid illnesses and the development of complicating S aureus bacterial pneumonias. Despite optimal medical treatment, the mortality of influenza pneumonia was high and similar to that of the 1919 outbreak (Table 3 ). Due to the small sample size, the uncontrolled nature of our study, and the delay in initiating specific antiviral therapy, the impact of the neuraminidase inhibitors on the outcome of influenza pneumonia could not be determined.
Official reports for influenza activity in the United States in 1999 -2000 revealed that most cases (99.7%) were due to influenza A (H3N2) viruses. According to the Centers for Disease Control and Prevention, the percentage of physician visits for an influenza-like illness during the 1999 -2000 season was similar to that of the previous 5 years. 1 However, despite the release of the neuraminidase inhibitors, the peak mortality due to pneumonia and influenza during the 1999 -2000 season was 2% higher than the peak during the last two seasons (9.1% vs 11.2%, respectively). 1 In our institution, the recognized number of hospital admissions for influenza increased fourfold to sevenfold over previous years, much beyond what would be expected considering official reports for influenza activity in the United States. We believe that the increase in the number of influenza cases seen in our institution was due to improvements in diagnosis with the availability of rapid diagnostic techniques. In addition, it is likely that increased public awareness of influenza due to the intense media coverage during the 1999 -2000 season may have impacted on the number of patients tested for influenza. It is unlikely that false-positive results were included in our series since specificities for the rapid viral tests are high (range, 90 to 99%). [5] [6] [7] [8] [9] It is more likely that the total number of influenza cases was underestimated, because sensitivities can be as low as 65% (range, 65 to 96%). In our study, rapid diagnosis was helpful in the institution of antiviral treatment and control measures, such as respiratory isolation. The latter is of major importance since intrahospital outbreaks of influenza have been reported. 10 Characteristics of patients in this series are similar to those reported in previous studies (Table 3) . [11] [12] [13] [14] [15] [16] [17] [18] [19] In almost all series, the majority of the patients who developed pneumonia were old and had severe comorbid conditions, such as heart disease, COPD, renal disease, diabetes, and immunosuppression. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] However, serious influenza pneumonia has also occurred in previously healthy patients. In this series, 2 of the 17 patients (11.7%) who developed influenza pneumonia had no reported comorbid illness. One of those patients was an unvaccinated 33-year-old woman who developed an initial right lower lobe infiltrate followed by superimposed bacterial infections, respiratory failure, and death. Shortness of breath was the only symptom that distinguished patients with pneumonia from those with a URI Table 2 for expansion of abbreviations. †The minority of patients were confirmed to have influenza virus infection. ‡Assumed to be young adults (soldiers).
alone. Consequently, patients with features of influenza and shortness of breath should undergo chest radiography to exclude pneumonia. As seen in Table  3 , as well as several other autopsy series, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] S pneumoniae (29 to 48%) and S aureus (7 to 40%) have been the most common bacterial isolates causing superimposed infections in patients with influenza pneumonia. Haemophilus influenzae, 16, 24 Pseudomonas aeruginosa, 15 and herpes virus 26 are less commonly implicated. In this series, S aureus was the most common bacterial pathogen isolated. The high prevalence of methicillin-resistant S aureus (MRSA) was rather surprising. However, this finding may be related to the fact that these patients had serious comorbid diseases and/or it may reflect local resistance patterns. Based on these findings, antistaphylococcal antibiotic therapy (with MRSA activity in MRSA endemic regions) should be initiated in hospitalized cases of influenza pneumonia while culture and sensitivity data are pending. The theories proposed for the high incidence of superimposed bacterial infections in influenza pneumonia emphasize the synergistic effects of viral and bacterial pathogens to produce lung injury. Hers and Mulder 27 suggested that influenza virus can directly damage the respiratory epithelium, allowing free access to invading bacteria. It has also been demonstrated that some Staphylococcus and Streptococcus strains may increase viral replication and pathogenicity, contributing to influenza viral pneumonia. 28, 29 The findings of premortem and postmortem lung specimens also suggest a combined role for both bacterial and viral pathogens, although lesions compatible with an uncomplicated viral pneumonia have been widely described. 27,30 -33 Mortality associated with influenza pneumonia is high. The mortality rate in this series of 29.4% is similar to rates reported in other series over the past 100 years. There was also significant morbidity associated with influenza pneumonia, as seen by the number of ventilator days and the hospital LOS (Table 3 ). The persistently high morbidity and mortality associated with influenza pneumonia, despite advances in diagnosis and treatment, can be partially explained by the increased number of people at risk for the development of influenza respiratory complications (aging, etc). Although vaccination among elderly and other high-risk groups has been shown to reduce hospitalization, pneumonia, and death, 34 -36 the benefits of vaccination are not universal. In this study, none of the vaccinated patients died, but significant morbidity was seen in two vaccinated patients in whom pneumonia developed. The role of specific influenza antiviral agents in reducing mortality is uncertain. In the past, treatment has been limited to amantadine and rimantadine, 37 but more recently, inhaled zanamivir and oral oseltamivir, two new neuraminidase inhibitors, have been approved for the treatment of mild influenza infection. 38 -41 To date and to our knowledge, the efficacy of these new antiviral agents in patients with influenza pneumonia is unknown and no information is available on their bioavailability in critically ill patients. In this study, oral oseltamivir and rimantadine were the preferred antiviral medications due to easier administration in critically ill patients and in patients receiving mechanical ventilation. Due to the small number of patients and the uncontrolled nature of our study, we were not able to assess the efficacy of treatment with oseltamivir. Furthermore, there was a delay (on average 4 days) between the onset of symptoms and the initiation of antiviral therapy in the patients with influenza pneumonia. The neuraminidase inhibitors are approved for use within the first 48 h of the onset of symptoms. The rapid identification and treatment (within 48 h) of patients with an influenza-like illness who are at risk of developing influenza pneumonia (the elderly and those with comorbid diseases, especially COPD) with the new neuraminidase inhibitors may reduce the incidence and/or severity of influenza pneumonia.
In summary, we describe our experience with influenza A respiratory complications in the 1999 -2000 season. The recognized number of hospital admissions for influenza to our hospital increased fourfold to sevenfold over previous years, likely due to the implementation of rapid diagnostic tests and heightened awareness of the disease. S aureus was the most common bacterial isolate associated with influenza pneumonia, and appropriate coverage for this organism should be given to patients hospitalized with influenza pneumonia. Hospitalization of patients with influenza with pneumonia occurred in both previously healthy and immunocompromised patients and had a high morbidity and mortality. The effectiveness of specific antiviral agents in treating influenza pneumonia remains to be determined.
